For European medical/trade media only: New data for Kisplyx® (lenvatinib) plus Keytruda® (pembrolizumab) published in the New England Journal of Medicine demonstrate significant improvement in progression free survival and overall survival versus standard of care in advanced renal cell carcinoma
You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.
Click 'cancel' to return to Eisai's site or 'continue' to proceed.
You are now leaving eisai.eu
You have selected a link that will take you to another Eisai website.
Click ‘cancel’ to return to eisai.eu or ‘continue’ to proceed.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.